TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11109297
Drug: Intermittent (premenstrual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent (premenstrual only) treatment with SSRIs
Study: 8866346
Drug: Tagetes patula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tagetes patula preparations plus protective pad
Study: 1471435
Drug: Comprehensive team
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comprehensive team care (CC)
Study: 6318224
Drug: Enalapril (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5, 10 and 20 mg twice daily)
Study: 6318224
Drug: Propranolol (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40, 80 and 120 mg twice daily)
Study: 30420001
Drug: In-treatment expectancy
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-treatment expectancy during antidepressant treatment
Study: 30420001
Drug: Gap between
Normalized name: GAP JUNCTION ALPHA-3 PROTEIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gap between expected treatment outcomes and actual depressive severity
Study: 26813890
Drug: Long-chain n-3
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-chain n-3 polyunsaturated fatty acids intake meeting the recommendation (≥500 mg/day)
Study: 22891212
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of triglycerides plus heparin
Study: 22891212
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of glycerol
Study: 17000647
Drug: Continuous oral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous oral progestin
Study: 16277782
Drug: GOS/FOS formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: GOS/FOS formula (6 g/l)
Study: 7782965
Drug: Primary-surgical regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary-surgical regimen (Group A): total pharyngo‐laryngo‐esophagectomy after 20 Gy irradiation therapy. Chemotherapy was combined in some patients.
Study: 7782965
Drug: Primary-radiotherapeutic regimen
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary-radiotherapeutic regimen (Group B): radiation therapy (60 Gy) with chemotherapy (UFT 300 to 600 mg/day; some patients received 1-2 courses of intravenous cisplatinum).
Study: 2109951
Drug: Urapidil (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (bolus injections of 25, 25 and 50 mg, followed by an infusion of 180 ml/h)
Study: 6106469
Drug: Pindolol (beta-blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (beta-blocking drug)
Study: 19936457
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 100 x 10^6 mononuclear cells (Arterial Group)
Study: 19936457
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 100 x 10^6 mononuclear cells (Venous Group)
Study: 16253719
Drug: Erythropoietin alfa
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin alfa treatment group (n=78), median final dose 2,000 IU/wk
Study: 16253719
Drug: Control/delayed treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/delayed treatment group (n=94), median final dose 3,000 IU/wk
Study: 16253719
Drug: Erythropoietin alfa
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin alfa treatment group
Study: 7821104
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/day) alone
Study: 7821104
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg/day) plus plaunotol (240 mg/day)
Study: 331994
Drug: Guanethidine 3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanethidine 3% - adrenaline 0.5% (G-A)
Study: 16929421
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg oral misoprostol every 4 h (treatment group 1)
Study: 16929421
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg oral misoprostol every 4 h (treatment group 2)
Study: 16929421
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin B6 50 mg, control)
Study: 12922104
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of Avaxim pediatric hepatitis A vaccine given at 6 months of age (Group 2)
Study: 12922104
Drug: Priming dose
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming dose of Avaxim pediatric hepatitis A vaccine given 2 weeks after routine vaccinations (Group 1)
Study: 1294401
Drug: hCG (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG (10,000 IU i.m. on first diagnosis of pregnancy, 5000 IU twice weekly to week 12, then once weekly to week 16)
Study: 29795527
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tadalafil once a day
Study: 29795527
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg tadalafil on-demand (four times a month)
Study: 23322261
Drug: Alexander Technique
Normalized name: Nerium oleander flower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alexander Technique (AT) with 12 weekly home-based lessons in addition to usual care
Study: 23071635
Drug: Testosterone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (50 mg transdermal administration)
Study: 20191485
Drug: Anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumor necrosis factor therapy (exact dosage and duration not specified)
Study: 7097422
Drug: Protein supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supplement isolated from mature human milk, increasing protein content by 0.8 gm/dl
Study: 29578832
Drug: Daily motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily motivational text messages, additional texted tips in response to keywords, and weekly study questions
Study: 29578832
Drug: Weekly study
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly study questions only
Study: 10440416
Drug: Clopidogrel 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 50 mg once daily
Study: 20844075
Drug: 100% Concord
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100% Concord grape juice (7 mL · kg⁻¹ · d⁻¹)
Study: 16094738
Drug: Sequential radical
Normalized name: Campsis radicans flower extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radical radiotherapy and cisplatin-based chemotherapy
Study: 12084743
Drug: Trabeculectomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabeculectomy with intraoperative antimetabolites (5‐fluorouracil 25 mg/ml, mitomycin C 0.2 mg/ml and 0.4 mg/ml)
Study: 12084743
Drug: Viscocanalostomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscocanalostomy with intraoperative intracanalicular Healonid GV injection
Study: 12084743
Drug: Viscocanalostomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscocanalostomy with balanced saline solution
Study: 2296627
Drug: Moclobemide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide (200 mg t.i.d.)
Study: 2296627
Drug: Clomipramine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (25 mg b.i.d.)
Study: 2296627
Drug: Alcohol (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.6 g/l blood alcohol concentration)
Study: 31090488
Drug: Ketamine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.8 mg/kg mixed in juice, administered 30 minutes before procedure)
Study: 17102644
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate (MCC) vaccines administered at the same time as DT/Td boosters
Study: 17102644
Drug: Meningococcal C
Normalized name: meningococcal conjugate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal C conjugate (MCC) vaccines administered a month before or after DT/Td boosters
Study: 17102644
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of analgesics/antipyretic medication
Study: 17102644
Drug: MCC vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCC vaccines under the above schedules
Study: 11269570
Drug: Tolterodine L-tartrate
Normalized name: Tolterodine L-tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine L-tartrate 2 mg administered with a standardized medium-fat breakfast
Study: 11269570
Drug: Tolterodine L-tartrate
Normalized name: Tolterodine L-tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine L-tartrate 2 mg administered on an empty stomach
Study: 10998085
Drug: Nitroglycerine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (1 mg h‐1)
Study: 10998085
Drug: Nitroglycerine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (2 mg h‐1)
Study: 8792277
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml of milk containing B. longum B6 grown with lactose
Study: 8792277
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml of milk containing B. longum B6 grown with lactose plus glucose
Study: 8792277
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml of milk containing B. longum ATCC 15708 grown with lactose
Study: 8792277
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml of lowfat milk (control)
Study: 1379256
Drug: GHRH-(1-29) high
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH-(1-29) high dose (1 mg) sc injections twice daily for 14 days
Study: 1379256
Drug: GHRH-(1-29) low
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH-(1-29) low dose (0.5 mg) sc injections twice daily for 14 days
Study: 30711987
Drug: Comprehensive pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comprehensive pharmaceutical interventions
Study: 26782102
Drug: Intravenous glyceryltrinitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glyceryltrinitrate (GTN) at a maximum tolerable dosage (6.2 ± 1.5 mg/h)
Study: 26782102
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of iloprost (10 μg/mL)
Study: 26782102
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: intravenous or inhaled sodium chloride (NaCl) 0.9%
Study: 19406521
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis indicated in all patients; overall adequacy of prophylaxis according to hospital protocol was 89.1%
Study: 17664057
Drug: Anti-inflammatory blend
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory blend rich in polyunsaturated fatty acids (alpha-linolenic acid, 240 mg/d; eicosapentaenoic acid, 120 mg/d; stearidonic acid, 49 mg/d; gamma-linolenic acid, 73 mg/d)
Study: 17664057
Drug: Inflammatory fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inflammatory fat blend (arachidonic acid, 40 mg/d)
Study: 15841721
Drug: Correlation between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation between Helicobacter DNA and IgG antibody responses
Study: 12200947
Drug: Target-controlled propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target-controlled propofol and target-controlled remifentanil (3 ng mL‐1)
Study: 12200947
Drug: Midazolam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.03 mg kg‐1), target-controlled remifentanil (3 ng mL‐1) and target-controlled propofol
Study: 7635409
Drug: Interferon alfa
Normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alfa (IFN‐alpha) treatment for 4 months
Study: 2792176
Drug: Lactitol (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactitol (20-40 g per day for one month)
Study: 28849265
Drug: Intraoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative chemotherapy (portal vein chemotherapy, intraluminal chemotherapy, and intraperitoneal chemotherapy) plus surgery
Study: 26090383
Drug: RBTM (rabeprozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBTM (rabeprozole 20 mg bid., bismuth subcitrate 120 mg qid, tetracycline 500 mg qid, and metronidazole 250 mg qid)
Study: 26090383
Drug: RATM (rabeprozole
Approvals — FDA: no, EMA: no, PMDA: no
Description: RATM (rabeprozole 20 mg bid., amoxicillin 1 g bid., tetracycline 500 mg qid, and metronidazole 250 mg qid)
Study: 23497763
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS 50 mg after a high-fat breakfast
Study: 23497763
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS 50 mg after a low-fat breakfast
Study: 23497763
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS 100 mg after a high-fat breakfast
Study: 23497763
Drug: Mirabegron OCAS
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirabegron OCAS 100 mg after a low-fat breakfast
Study: 21258027
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy for smoking cessation
Study: 21258027
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy for smoking cessation (short-term follow-up ≤ 12 weeks)
Study: 21258027
Drug: Pharmacologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic therapy for smoking cessation (mid-term follow-up 26 weeks)
Study: 15590048
Drug: Piecewise splines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piecewise splines and rescue (treatment adjustment)
Study: 8424497
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of glucose mixed with 100 U of human insulin (HI/100)
Study: 8424497
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of glucose mixed with 100 U of bovine insulin (BI/100)
Study: 8424497
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of glucose mixed with 50 U of human insulin (HI/50)
Study: 8424497
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of glucose mixed with 50 U of bovine insulin (BI/50)
Study: 25365778
Drug: Mindful awareness
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mindful awareness and acceptance treatment (M)
Study: 24024323
Drug: Erbanxiao solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erbanxiao solution
Study: 24024323
Drug: Compound Kushen
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Kushen injection
Study: 12554382
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in a rehabilitation centre in Tenerife for four weeks (Group 1, n=30)
Study: 12554382
Drug: Treatment in
Normalized name: Other agents for local oral treatment in ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment in two similar centres in Norway for four weeks (Group 2, n=29)
Study: 24155106
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.2 g of elemental calcium in the form of calcium carbonate)
Study: 24155106
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (in women taking at least 80% of the supplements)
Study: 24155106
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium intake (diet and supplements)
Study: 9175948
Drug: Ibuprofen 1
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 1 x 10 mg/kg, followed by 5 mg/kg 24 and 48 hours later
Study: 9175948
Drug: Indomethacin 3
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin 3 x 0.2 mg/kg at 12 hour intervals
Study: 3547369
Drug: Ceforanide (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceforanide (two 1 gm doses)
Study: 3547369
Drug: Cephalothin (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalothin (five doses)
Study: 27144905
Drug: High-dose prednisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisone (60 mg/day)
Study: 27144905
Drug: Low-dose prednisone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisone (15 mg/day)
Study: 27144905
Drug: Medium-dose prednisone
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium-dose prednisone (30 mg/day)
Study: 21294416
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg noni extract
Study: 21294416
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg noni extract
Study: 21294416
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg noni extract
Study: 3730529
Drug: Promethazine 50
Normalized name: promethazine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 50 mg (innovator dosage form)
Study: 3730529
Drug: Promethazine 50
Normalized name: promethazine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 50 mg (generic dosage form)
Study: 3730529
Drug: Promethazine 50
Normalized name: promethazine 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine 50 mg (solution dosage form)
Study: 23924290
Drug: Methylphenidate (MP)
Normalized name: 6 MP
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MP) at 0.3 mg/kg twice daily for 2 weeks
Study: 10867042
Drug: Tomato juice
Normalized name: TOMATO JUICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato juice (330 mL/d, 47.1 mg/d lycopene)
Study: 8104724
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine 4.0 mg
Study: 8104724
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 0.4 mg
Study: 27009108
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 μg twice a day for 4 weeks, then 10 μg twice a day)
Study: 23901094
Drug: Daily acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily acyclovir 400 mg twice daily
Study: 20141265
Drug: Nonpsychodynamic therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpsychodynamic therapies
Study: 20823824
Drug: Cytoflavin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20 ml/day intravenous for 10 days, then 2 tablets twice a day for 25 days)
Study: 20823824
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy only (comparison group)
Study: 15840055
Drug: Alfacalcidol 0.5
Normalized name: alfacalcidol 0.5 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol 0.5 microg PO daily
Study: 15840055
Drug: Intranasal salmon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal salmon calcitonin 200 IU every other day
Study: 11964564
Drug: 4‐Methylpyrazole (10‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐Methylpyrazole (10‐15 mg/kg orally)
Study: 9548634
Drug: Drug-free detention
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug-free detention treatment program (DVA)
Study: 2850322
Drug: LMW heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW heparin (Fluxum) at doses of 4,000 or 8,000 I.U. Axa once a day by subcutaneous injection
Study: 2850322
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin at doses of 5,000 I.U. two or three times a day by subcutaneous injection
Study: 31721026
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment for 1 year
Study: 31721026
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (other hypoglycemic agents) for 1 year
Study: 26362578
Drug: ω‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs) 1.2 g/day for 12 weeks
Study: 26617271
Drug: Fennel 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fennel 5% vaginal cream (5 g/day for 8 weeks)
Study: 24159791
Drug: Mexicor used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexicor used in combined therapy with statins for atherogenic dyslipidemia
Study: 20564380
Drug: High-dose ursodeoxycholic
Normalized name: ursodeoxycholate
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ursodeoxycholic acid (UDCA) treatment (28-30 mg/kg/day)
Study: 12509613
Drug: Clenoliximab (0.05,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenoliximab (0.05, 0.2, 1, 5, 10 or 15 mg/kg; 150 or 350 mg weekly x 4; or 350 or 700 mg every other week x 2)
Study: 12509613
Drug: Clenoliximab (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clenoliximab (higher doses, less frequently)